文献速递肾小球疾病急性肾损伤

早期依库珠单抗改善儿童狼疮肾炎合并TMA肾脏结局

Early eculizumab treatment improves renal outcomes in pediatric lupus nephritis with thrombotic microangiopathy.
PubMed 文献 · Nephrol Dial Transplant · 2026-01-01

本研究回顾性分析2009年7月至2025年1月诊断为狼疮肾炎合并血栓性微血管病(LN-TMA)的22例儿童,其中4例接受依库珠单抗治疗,18例对照。依库珠单抗组在1周内血清肌酐显著下降、eGFR改善并持续至16周,部分肾脏缓解时间更短(1.67 vs 3.64个月,P<.05),1年完全缓解率更高(P=.003),无死亡或严重感染。

要点

  • 儿童LN-TMA中早期使用依库珠单抗可加速肾功能恢复。
  • 依库珠单抗组部分肾脏缓解时间短于常规治疗组。
  • 1年完全缓解率依库珠单抗组优于对照组(P=.003)。

核心结论

  • 在儿童狼疮肾炎合并TMA中,依库珠单抗较常规治疗加速肾脏恢复,早期使用可能减轻肾损伤并改善结局。

研究设计与样本

  • 回顾性分析2009年7月至2025年1月诊断为LN-TMA的儿童,共22例,其中4例接受≥1剂依库珠单抗,18例为对照。

主要发现

  • 依库珠单抗组在第1周血清肌酐显著下降、eGFR改善并持续至16周,对照组至第8周才延迟改善。
  • 依库珠单抗组部分肾脏缓解时间短于对照组(1.67 vs 3.64个月,P<.05)。
  • 依库珠单抗组完全肾脏缓解率有更高趋势(100% vs 50.0%,P=.29),Kaplan-Meier分析显示1年完全缓解率更优(P=.003)。
  • 依库珠单抗组血红蛋白恢复更快,无死亡或严重感染发生。

关键数值与推荐

  • TMA诊断需微血管病性溶血性贫血、血小板减少和器官受累,并排除TTP、志贺毒素相关HUS、抗磷脂抗体综合征、感染、高血压或药物所致TMA。
  • 所有患者符合2019 EULAR/ACR SLE分类标准且年龄<18岁。
  • 依库珠单抗在TMA诊断后约7天开始使用。

临床怎么用

  • 对于儿童LN-TMA,在排除TTP、感染和药物相关原因后,可考虑早期使用依库珠单抗以加速肾脏恢复。

局限性

  • 本研究为回顾性研究,样本量小, findings 需更大规模临床研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease. Patients with lupus nephritis (LN) complicated by thrombotic microangiopathy (TMA) exhibit high mortality and poor renal outcomes. Eculizumab, a humanized monoclonal antibody inhibiting terminal complement C5 activation, has been recommended for the treatment of TMA caused by alternative complement pathway activation. This study evaluated the clinical efficacy of eculizumab in pediatric LN-associated TMA. METHODS: We retrospectively analyzed children diagnosed with LN-TMA from July 2009 to January 2025. All patients met the 2019 EULAR/ACR SLE classification criteria and were aged <18 years. TMA diagnosis required microangiopathic hemolytic anemia, thrombocytopenia, and organ involvement, excluding TTP (ADAMTS13 deficiency), Shiga toxin-associated HUS, antiphospholipid antibody syndrome, infections, hypertension, or drug-induced TMA. Overall survival, renal response, and hematologic recovery were analyzed. RESULTS: Among 22 LN children with TMA, four received ≥1 dose of eculizumab (eculizumab group), while 18 served as controls. Baseline characteristics showed no significant differences. Eculizumab treatment was initiated ∼7 days following TMA diagnosis. By week 1, the eculizumab group demonstrated significant reductions in serum creatinine and improved eGFR, sustained through 16 weeks, whereas controls showed delayed improvement by week 8. Time to partial renal response was shorter with eculizumab (1.67 vs. 3.64 months, P < .05). Complete renal remission rates trended higher with eculizumab (100% vs. 50.0%, P = .29). Kaplan-Meier analysis confirmed superior 1-year complete remission rates in the eculizumab group (P = .003). Hemoglobin recovery was faster with eculizumab. No deaths or severe infections occurred, affirming its safety. CONCLUSION: In pediatric LN with TMA, eculizumab outperforms conventional therapy by accelerating renal recovery. Early use-after excluding TTP, infections, and drug-related causes-may mitigate renal damage and improve outcomes. Given that this is a retrospective study with a small sample size, the findings require validation from larger-scale clinical studies.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Yu S, Zhang J, He J, et al. Early eculizumab treatment improves renal outcomes in pediatric lupus nephritis with thrombotic microangiopathy. Nephrol Dial Transplant. 2026. PMID: 41686150. doi:10.1093/ndt/gfag031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。